Portland, OR, March 11, 2020 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the Human Growth Hormone Industry was projected at $2.84 billion in 2018 and is anticipated to reach $5.56 billion by 2026, growing at a CAGR of 8.6% from 2019 to 2026. The report provides comprehensive analyses of the top investment pockets, key drivers & opportunities, major market segments, and competitive landscape.
Request Sample Report at https://www.alliedmarketresearch.com/request-sample/6425
Increase in usage of growth hormone to control aging and surge in disorders related to growth hormone deficiency propel the growth of the global human growth hormone (hGH) market. On the other hand, several side effects related with the treatment impede the growth to some extent. However, rise in awareness toward usage of human growth hormone in developing economies is expected to offer multiple opportunities to the industry.
Based on application, the turner syndrome segment held the major share in 2018, contributing nearly one-third of the global human growth hormone (hGH) market. The segment is expected to dominate the market throughout the forecast period. On the other hand, the growth hormone deficiency segment would cite the fastest CAGR of 9.9% in between 2019 to 2026.
Based on route of administration, the subcutaneous segment accounted for nearly two-thirds of the global human growth hormone market (hGH) share in 2018, and is expected to dominate during the study period. In addition, the same segment is expected to portray the fastest CAGR of 9.1% by 2026.
For Purchase Enquiry at https://www.alliedmarketresearch.com/purchase-enquiry/6425
Based on geography, North America contributed to nearly half of the global human growth hormone market (hGH) revenue in 2018, and is projected to rule the roost throughout the estimated period. At the same time, the Asia-Pacific region is estimated to grow at the fastest CAGR of 10.2% during the forecast period.
Key market players analyzed in the research include Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Novartis AG, AnkeBio Co. Ltd, Novo Nordisk, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd, Ipsen, and Ferring BV.
Similar Reports:
AR in healthcare Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Digital Diabetes Management Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Inhalation Anesthesia Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Surgical lights Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Pharmaceutical Filtration Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.